Ozempic, Wegovy, and Other GLP-1s: New Treatment Options, New Service Expansion Opportunities

Session Description: Researchers are exploring using glucagon-like peptide-1 receptor agonists (GLP-1 drugs such as Wegovy, Mounjaro, Zepbound, Trulicity, and Ozempic) for substance use disorder (SUD) and alcohol use disorder (AUD) treatment. These medications are being used to manage weight loss and diabetes, although none are FDA approved for SUD/AUD, and some treatment providers are using them to address cravings. Panelists will discuss the possibilities of these drugs to improve patient outcomes, the opportunity to expand services, the reimbursement landscape, concerns about diversion and misuse, and other factors executives should consider.